At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 35 target
Drug / intervention
Nivolumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
In Brief
A Phase 1 clinical trial evaluating Nivolumab, HC-7366, and 1 other intervention for Phase 1b and 3 related conditions. Currently recruiting, targeting 35 participants across 1 site.
Detailed Summary
To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhase 1b, HC-7366, SHARK, Kidney Cancer
CountriesUnited States
CollaboratorsHiberCell, Inc.
Timeline
Phase 1Recruiting
2027202820292030
First PostedFeb 2026
Enrollment StartMar 2026
TodayJul 2026
Primary CompletionNov 2027
Study CompletionNov 2029
First PostedFeb 11, 2026
Enrollment StartMar 24, 2026
Primary CompletionNov 30, 2027
Study CompletionNov 30, 2029
TodayJul 1, 2026
Enrollment to primary: 1.7 yearsPosted 5 months agoPrimary completion in 1.4 years
Interventions
Nivolumabdrug
Given by IV
HC-7366drug
Given by po
ipilimumabdrug
Given by IV